1. Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious Diseases Society of America Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Bacterial Respiratory Infections Slide Set

2. These slides were developed using recommendations published in May 2013. The intended audience is clinicians involved in the care of patients with HIV. Users are cautioned that, because of the rapidly changing field of HIV care, this information could become out of date quickly. Finally, it is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent. – AETC National Resource Center http://www.aidsetc.org About This Presentation June 2013www.aidsetc.org 2

3.  Epidemiology  Clinical Manifestations  Diagnosis  Prevention  Treatment  Considerations in Pregnancy Bacterial Respiratory Infections June 2013www.aidsetc.org 3

4.  Bacterial pneumonia is a common cause of HIV- related morbidity  In HIV-infected persons:  Higher rates of bacterial pneumonia  Higher mortality  Increased incidence of bacteremia (esp. with S pneumoniae)  Can occur at any CD4 count or stage of disease  Recurrent pneumonia (≥2 episodes in 1 year) is an AIDS-defining condition Bacterial Respiratory Disease: Epidemiology June 2013www.aidsetc.org 4

5.  Incidence lower with use of ART  Risk factors include  Low CD4 count (<200 cells/µL)  No or intermittent use of ART  Cigarette smoking  Injection drug use  Chronic viral hepatitis Bacterial Respiratory Disease: Epidemiology (2) June 2013www.aidsetc.org 5

6.  Organisms:  S pneumoniae  Drug-resistant strains are increasingly common  H influenzae  P aeruginosa  S aureus, including MRSA  Atypicals (infrequent) Bacterial Respiratory Disease: Epidemiology (3) June 2013www.aidsetc.org 6

7.  Presentation similar to that of HIV uninfected, with acute symptoms (fevers, chills, rigors, chest pain, productive cough, dyspnea)  Subacute illness suggests alternative diagnosis (PCP, TB, chronic fungal disease, etc)  Physical exam: evidence of focal consolidation or pleural effusion  WBC usually elevated, may see left shift Bacterial Respiratory Disease: Clinical Manifestations June 2013www.aidsetc.org 7

8.  Assess disease severity (including signs of sepsis) and arterial oxygenation in all patients  Pneumonia Severity Index (PSI) appears valid for HIV-infected patients Bacterial Respiratory Disease: Clinical Manifestations (2) June 2013www.aidsetc.org 8

9. June 2013www.aidsetc.org 9 Chest X ray: pneumococcal pneumonia showing right middle lobe consolidation Credit: C. Daley, MD; HIV InSite  Chest X ray: Commonly shows unilateral, focal, segmental, or lobar consolidation, but may show atypical presentations (multilobar, nodular, reticulonodular) Bacterial Respiratory Disease: Diagnosis

10.  CAP diagnosis and management guidelines apply to HIV- infected as well as HIV-uninfected patients  Chest X ray: PA and lateral, if possible  Consider the possibility of specific pathogens, eg:  TB: if compatible clinical and X-ray presentation, manage as potential TB, pending test results  PCP: evaluate if clinically indicated (PCP may coexist with bacterial pneumonia)  P aeruginosa: if CD4 ≤50 cells/µL, preexisting lung disease, neutropenia, on corticosteroids, recent hospitalization, or residence in a health care facility  S aureus: if recent influenza or other viral infection, history of injection drug use, or severe bilateral necrotizing pneumonia Bacterial Respiratory Disease: Diagnosis (2) June 2013www.aidsetc.org 10

11.  Microbiologic diagnosis allows targeted treatment of specific pathogen(s)  Test to identify specific pathogens that would significantly alter standard (empirical) management decisions, if their presence is suspected  For patients well enough to be treated as outpatient: routine testing for etiology is optional  For hospitalized patients with suspected CAP: Gram stain and culture of expectorated sputum specimen, 2 blood cultures  Gram stain and culture of expectorated sputum only if good quality specimen as well as good lab performance measures  Endotracheal aspirate sample for intubated patients  Consider bronchoscopy with BAL lavage if differential includes pathogens such as P jiroveci Bacterial Respiratory Disease: Diagnosis (3) June 2013www.aidsetc.org 11

12.  Microbiologic diagnosis  Consider blood cultures for all:  Higher rate of bacteremia in HIV-infected patients with CAP  Higher risk of drug-resistant pneumococcal infection  Blood culture has high specificity but low sensitivity  Consider urinary antigen tests for L pneumophila and S pneumoniae  Consider diagnostic thoracentesis if pleural effusion Bacterial Respiratory Disease: Diagnosis (4) June 2013www.aidsetc.org 12

13.  No effective means of reducing exposure to S pneumoniae and H influenzae Bacterial Respiratory Disease: Preventing Exposure June 2013www.aidsetc.org 13

14.  Pneumococcal vaccine:  Recommended for all with HIV infection, regardless of CD4 count  23-valent pneumococcal polysaccharide vaccine (PPV23)  Multiple observational studies reported benefits including reduced risk of pneumococcal bacteremia  13-valent pneumococcal conjugate vaccine (PCV13)  Recommended for use in adults with HIV or other immunocompromising conditions  7-valent PCV  High efficacy against vaccine-type invasive pneumococcal disease in one study Bacterial Respiratory Disease: Preventing Disease June 2013www.aidsetc.org 14

15.  Pneumococcal vaccination recommendations  No previous pneumococcal vaccination  Preferred:  1 dose PCV13 followed by:  If CD4 ≥200 cells/µL: PPV23 should be given ≥8 weeks after PCV13  If CD4 200 cells/µL  Alternative:  1 dose PPV23  Previous PPV23 vaccination  1 dose of PCV13, to be given ≥1 year after last receipt of PPV23 Bacterial Respiratory Disease: Preventing Disease (2) June 2013www.aidsetc.org 15

16.  Pneumococcal vaccination recommendations (2)  Revaccination  Individuals who previously received PPV23  Duration of protective effect of PPV23 is not known  1 dose PPV23 recommended for age 19-64 years if ≥5 years since 1st dose of PPV  Another dose of PPV23 for age ≥65 if ≥5 years since previous PPV23  Single dose of PCV13 should be given if ≥1 year since previous PPV23  Subsequent doses of PPV23 as above  No more than 3 lifetime doses of PPV23 Bacterial Respiratory Disease: Preventing Disease (3) June 2013www.aidsetc.org 16

17.  Influenza vaccine:  Recommended annually during influenza season (bacterial pneumonia may occur as complication of influenza)  Live attenuated vaccine is contraindicated and is not recommended for HIV-infected persons Bacterial Respiratory Disease: Preventing Disease (4) June 2013www.aidsetc.org 17

18.  H influenzae type B vaccine:  Not usually recommended for adults, unless anatomic or functional asplenia (low incidence of infection) Bacterial Respiratory Disease: Preventing Disease (5) June 2013www.aidsetc.org 18

19.  Antiretroviral therapy: reduces risk of bacterial pneumonia  TMP-SMX and macrolides: reduce frequency of bacterial respiratory infections when given as prophylaxis for PCP or MAC, respectively  These should not be prescribed solely to prevent bacterial respiratory infections  Behavioral interventions:  Cessation of smoking, injection drug use, alcohol use Bacterial Respiratory Disease: Preventing Disease (6) June 2013www.aidsetc.org 19

20.  Outpatient versus inpatient treatment:  Severity of disease and CD4 count may both be important  Mortality higher with higher PSI class, with CD4 <200 cells/µL  Some offer hospitalization to all CAP patients with CD4 200 cells/µL  Basic principles of treatment are same as those for HIV uninfected Bacterial Respiratory Infections: Treatment June 2013www.aidsetc.org 20

21.  Target most common pathogens, particularly S pneumoniae and H influenzae  Empiric treatment should be started promptly  Specimens for diagnosis should be collected before antibiotics are given  Modify treatment, if indicated, based on microbiologic and drug susceptibility results  Fluoroquinolones should be used cautiously if TB suspected but not being treated (risk of TB monotherapy)  Empiric macrolide monotherapy cannot be routinely recommended (risk of macrolide-resistant S pneumoniae) Bacterial Respiratory Infections: Treatment (2) June 2013www.aidsetc.org 21

22.  Outpatient treatment (empiric)  Preferred:  Oral beta-lactam + macrolide (azithromycin, clarithromycin)  Preferred beta-lactams: high-dose amoxicillin or amoxicillin-clavulanate  Alternative beta-lactams: cefpodoxime, cefuroxime  Fluoroquinolone, especially if penicillin allergy  Levofloxacin 750 mg PO QD  Moxifloxacin 400 mg PO QD  Alternative: beta-lactam + doxycycline  Duration of therapy: 7-10 days for most; minimum 5 days  Should be afebrile for 48-72 hours, clinically stable Bacterial Respiratory Infections: Treatment (3) June 2013www.aidsetc.org 22

23.  Hospitalized, non-ICU treatment (empiric)  Preferred:  IV beta-lactam + macrolide (azithromycin, clarithromycin)  Preferred beta-lactams: ceftriaxone, cefotaxime, ampicillin- sulbactam  IV fluoroquinolone, especially if penicillin allergy  Levofloxacin 750 mg IV QD  Moxifloxacin 400 mg IV QD  Alternative:  IV beta-lactam + doxycycline  IV penicillin for confirmed pneumococcal pneumonia Bacterial Respiratory Infections: Treatment (4) June 2013www.aidsetc.org 23

24.  Inpatient, ICU (empiric)  Preferred:  IV beta-lactam + IV azithromycin  IV beta-lactam + (levofloxacin 750 mg IV QD or moxifloxacin 400 mg IV QD)  Preferred beta-lactams: ceftriaxone, cefotaxime, ampicillin- sulbactam  Alternative:  Penicillin allergy: aztreonam IV + IV levofloxacin or moxifloxacin as above Bacterial Respiratory Infections: Treatment (5) June 2013www.aidsetc.org 24

25.  Most CAP pathogens can be treated with the recommended regimens  Exceptions: P aeruginosa and S aureus (including community-acquired MRSA)  Empiric coverage may be warranted, if either is suspected  Diagnostic tests (sputum Gram stain and culture) likely to be of high yield Bacterial Respiratory Infections: Treatment (6) June 2013www.aidsetc.org 25

26.  Empiric Pseudomonas treatment  Preferred: antipneumococcal antipseudomonal beta- lactam + (ciprofloxacin 400 mg IV Q8-12H or levofloxacin 750 mg IV QD)  Preferred beta-lactams: piperacillin-tazobactam, cefepime, imipenem, meropenem  Alternative:  Beta-lactam as above + IV aminoglycoside + IV azithromycin  Beta-lactam as above + IV aminoglycoside + (moxifloxacin 400 mg IV QD or levofloxacin 750 mg IV QD)  Penicillin allergy: replace beta-lactam with aztreonam Bacterial Respiratory Infections: Treatment (7) June 2013www.aidsetc.org 26

27.  Empiric S aureus (including community-acquired MRSA) treatment:  Add vancomycin (IV) or linezolid (IV or PO) alone to the antibiotic regimen  For severe necrotizing pneumonia, consider addition of clindamycin to vancomycin (not to linezolid), to minimize bacterial toxin production Bacterial Respiratory Infections: Treatment (8) June 2013www.aidsetc.org 27

28.  When etiology of the pneumonia is identified, modify antimicrobial therapy to target that pathogen  Consider switch from IV to PO therapy: when improved clinically, able to tolerate PO medications, have intact GI function  Clinical stability: temperature 90% or PaO2 >60 mm Hg Bacterial Respiratory Infections: Treatment (9) June 2013www.aidsetc.org 28

29.  Initiate ART early in course of bacterial pneumonia  In one randomized study, early ART in setting of OIs (including bacterial infections) decreased AIDS progression and death Bacterial Respiratory Infections: Starting ART June 2013www.aidsetc.org 29

30.  Clinical response typically seen within 48-72 hours after start of appropriate antimicrobial therapy  Advanced HIV, CD4 7 days)  Patients on ART had shorter time to clinical stability  IRIS has not been described Bacterial Respiratory Infections: Monitoring and Adverse Events June 2013www.aidsetc.org 30

31.  If worsening symptoms/signs or no improvement, evaluate further for other infectious and noninfectious causes  Consider possibility of TB Bacterial Respiratory Infections: Treatment Failure June 2013www.aidsetc.org 31

32.  23-valent pneumococcal vaccine, as above  Influenza vaccine during influenza season  Antibiotic prophylaxis generally not recommended to prevent bacterial respiratory infections (potential for drug resistance and toxicity) Bacterial Respiratory Infections: Preventing Recurrence June 2013www.aidsetc.org 32

33.  Diagnosis as in nonpregnant adults (abdominal shielding during radiographic procedures)  Management as in nonpregnant adults, except:  Clarithromycin not recommended as first-line agent (birth defects in animals); azithromycin recommended when macrolide is indicated  Quinolones may be used for serious infections when indicated (no arthropathy or birth defects reported in exposed human fetuses)  Doxycycline not recommended (hepatoxicity, staining of fetal teeth and bones) Bacterial Respiratory Infections: Considerations in Pregnancy June 2013www.aidsetc.org 33

34.  Management:  Beta-lactams: no known teratogenicity or increased toxicity  Aminoglycosides: theoretical risk of fetal renal or eighth nerve damage, but not documented in humans except with streptomycin, kanamycin  Linezolid: limited data; not teratogenic in animal studies Bacterial Respiratory Infections: Considerations in Pregnancy (2) June 2013www.aidsetc.org 34

35.  Increased risk of preterm labor and delivery  If pneumonia after 20 weeks of gestation, monitor for contractions  Pneumococcal and influenza vaccines can be administered  Influenza vaccine recommended for all pregnant women during influenza season  During pregnancy, vaccines should be administered after ART has been initiated, to minimize transient HIV RNA increases that may be caused by vaccine Bacterial Respiratory Infections: Considerations in Pregnancy (3) June 2013www.aidsetc.org 35

36.  http://www.aidsetc.org  http://aidsinfo.nih.gov Websites to Access the Guidelines June 2013www.aidsetc.org 36

37.  This presentation was prepared by Susa Coffey, MD, for the AETC National Resource Center in June 2013  See the AETC NRC website for the most current version of this presentation: http://www.aidsetc.org About This Slide Set June 2013www.aidsetc.org 37